The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines

被引:0
作者
Subik, Kristina [1 ]
Lee, Jin-Feng [2 ]
Baxter, Laurie [1 ]
Strzepek, Tamera [1 ]
Costello, Dawn [1 ]
Crowley, Patti [1 ]
Xing, Lianping [1 ]
Hung, Mien-Chie [2 ,3 ,4 ]
Bonfiglio, Thomas [1 ]
Hicks, David G. [1 ]
Tang, Ping [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[3] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan
[4] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan
来源
BREAST CANCER-BASIC AND CLINICAL RESEARCH | 2010年 / 4卷
关键词
molecular classification; breast cancer; cell lines; immunohistochemistry;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers. The objective of this current project was to study the molecular classification of commonly used breast cancer cell lines by IHC analysis. Seventeen breast cancer cell lines were harvested, fixed in formalin and made into cell blocks. IHC analyses were performed on each cell block with antibodies to estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, CK5/6, Ki-67 and androgen receptor (AR). Among the 17 cell lines, MCF-7 and ZR-75-1 fell to Luminal A subtype; BT-474 to Luminal B subtype; SKBR-3, MDA-MD-435 and AU 565 to HER2 over-expression subtype; MDA- MB-231, MCF-12A, HBL 101, HS 598 T, MCF-10A, MCF-10F, BT-20, 468 and BT-483 to basal subtype. MDA- MB-453 belonged to Unclassified subtype. Since each subtype defined by this IHC-based molecular classification does show a distinct clinical outcome, attention should be paid when choosing a cell line for any study.
引用
收藏
页码:35 / 41
页数:7
相关论文
共 41 条
  • [1] Ki67 and cyclin A as prognostic factors in early breast cancer.: What are the optimal cut-off values?
    Ahlin, C.
    Aaltonen, K.
    Amini, R-M
    Nevanlinna, H.
    Fjallskog, M-L
    Blomqvist, C.
    [J]. HISTOPATHOLOGY, 2007, 51 (04) : 491 - 498
  • [2] Bertucci Francois, 2008, J Biol, V7, P6, DOI 10.1186/jbiol67
  • [3] Bonelli MA, 2010, BREAST CANC RES TREA
  • [4] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Carey, Lisa A.
    Perou, Charles M.
    Livasy, Chad A.
    Dressler, Lynn G.
    Cowan, David
    Conway, Kathleen
    Karaca, Gamze
    Troester, Melissa A.
    Tse, Chiu Kit
    Edmiston, Sharon
    Deming, Sandra L.
    Geradts, Joseph
    Cheang, Maggie C. U.
    Nielsen, Torsten O.
    Moorman, Patricia G.
    Earp, H. Shelton
    Millikan, Robert C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2492 - 2502
  • [5] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
    Cheang, Maggie C. U.
    Chia, Stephen K.
    Voduc, David
    Gao, Dongxia
    Leung, Samuel
    Snider, Jacqueline
    Watson, Mark
    Davies, Sherri
    Bernard, Philip S.
    Parker, Joel S.
    Perou, Charles M.
    Ellis, Matthew J.
    Nielsen, Torsten O.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10): : 736 - 750
  • [6] Intratumor heterogeneity of biomarker expression in breast carcinomas
    Chhieng, DD
    Frost, AR
    Niwas, S
    Weiss, H
    Grizzle, WE
    Beeken, S
    [J]. BIOTECHNIC & HISTOCHEMISTRY, 2004, 79 (01) : 25 - 36
  • [7] New Molecular Classifications of Breast Cancer
    Cianfrocca, Mary
    Gradishar, William
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2009, 59 (05) : 303 - 313
  • [8] Gokmen-Polar Y, 2010, BREAST CANC RES TREA
  • [9] Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast
    Hanley, Krisztina
    Wang, Jianmin
    Bourne, Patricia
    Yang, Qi
    Gao, Allen C.
    Lyman, Gary
    Tang, Ping
    [J]. HUMAN PATHOLOGY, 2008, 39 (03) : 386 - 392
  • [10] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    Harvey, JM
    Clark, GM
    Osborne, CK
    Allred, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1474 - 1481